Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome01:23

Irritable Bowel Syndrome

DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Helicobacter pylori eradication rate following first line non-bismuth quadruple therapy regimen in Tunisian patients: the HPERAD study.

BMC infectious diseases·2025
Same author

Colonic strictures in Crohn's disease: a non-surgical survival.

Future science OA·2025
Same author

Abnormal expression of oxylipins and related synthesizing/signaling pathways in inflammatory bowel diseases.

Prostaglandins, leukotrienes, and essential fatty acids·2024
Same author

Intestinal T-cell lymphoma not otherwise specified: a case report and literature review.

Future science OA·2024
Same author

Overlap syndrome of seronegative primary biliary cholangitis and small duct primary sclerosing cholangitis: a first case report and literature review.

Future science OA·2024
Same author

EncephalApp Stroop Test for covert hepatic encephalopathy screening in Tunisian cirrhotic patients.

F1000Research·2023

Related Experiment Video

Updated: May 23, 2026

A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium
04:05

A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium

Published on: May 31, 2024

[Post-infectious irritable bowel syndrome].

Meriem Serghini1, Sami Karoui, Jalel Boubaker

  • 1Service de Gastro-entérologie A. Hôpital la Rabta, Tunis.

La Tunisie Medicale
|April 7, 2012
PubMed
Summary

Post-infectious irritable bowel syndrome (PI-IBS) occurs after gastroenteritis, affecting 10% of individuals. This condition involves gut inflammation and altered permeability, with treatments similar to IBS.

Area of Science:

  • Gastroenterology
  • Immunology
  • Microbiology

Context:

  • Post-infectious irritable bowel syndrome (PI-IBS) is a distinct clinical entity.
  • It arises subsequent to acute gastroenteritis, impacting gut function.
  • Understanding PI-IBS is crucial for differentiating it from other functional gastrointestinal disorders.

Purpose:

  • To review the epidemiology, clinical presentation, and prognosis of PI-IBS.
  • To elucidate the underlying physiopathology of PI-IBS.
  • To explore current and novel treatment strategies for PI-IBS.

Summary:

  • PI-IBS incidence ranges from 4-32% (mean 10%), often triggered by bacterial infections.
  • Key risk factors include demographics, psychological status, and illness severity.

More Related Videos

Postoperative Ileus Murine Model
04:26

Postoperative Ileus Murine Model

Published on: July 12, 2024

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Related Experiment Videos

Last Updated: May 23, 2026

A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium
04:05

A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium

Published on: May 31, 2024

Postoperative Ileus Murine Model
04:26

Postoperative Ileus Murine Model

Published on: July 12, 2024

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

  • Common symptoms mimic diarrhea-predominant IBS, linked to increased intestinal permeability, mucosal inflammation (elevated lymphocytes, mast cells, enterochromaffin cells), and inflammatory cytokines.

    • Impact:

    • PI-IBS represents a novel concept in IBS research, necessitating tailored diagnostic and therapeutic approaches.
    • Identifying specific risk factors and pathophysiological mechanisms can lead to targeted interventions.
    • Further research into PI-IBS may reveal new avenues for managing functional bowel disorders.